mAb anti-Human Hepatocellular Carcinoma, CHALV1

Description

Description: Mouse monoclonal antibody to human hepatocellular carcinoma

Purification: Protein G affinity purified

Product Type: Primary antibody

Target Protein: Human hepato-cellular carcinoma related protein

Immunogen: Human liver carcinoma cells

Fusion Myeloma: Sp2/0-Ag14

Specificity: Using indirect immunofluorescence assay, this mAb showed positive reactions with 8 human hepato-cellular carcinoma cell lines and 12 human liver cancer surgical specimens tested. 

Species Reacitvity: Human, others not tested

Cross-reactivity: There were no detectable positive reactions with other human tumor cell lines and solid tumour specimens. Showed negative reaction to all normal human adult tissues and fetal tissues tested.

Host / Isotype: Mouse, IgG1 Kappa

Formulation: Lyophilized from a solution in 0.01M PBS, pH7.0

Reconstitution: Double distilled water is recommended to adjust the final concentration to 1.00mg/mL.

Storage: Store at -20^oC

Research Area: Oncology

Background:  

Hepatocellular carcinoma frequently occurs in individuals infected with hepatitis virus B and/or C, and in alcoholic persons with cirrhosis.  In countries where hepatitis is not epidemic, hepatocellular carcinoma is mostly metastatic cancers developed elsewhere in the body. At early stage, the cancer can be curable by surgical removal of small tumour if liver is in good condition or by transplantation if liver’s function is damaged because of disease. The cancer responds poorly to treatment at advanced stage.

Application: Indirect immunofluorescence assay

References:

If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.